A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
The study's primary objective [in a population of patients with MDS after failure of
treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival
(OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients
and in a subgroup of patients with IPSS-R very high risk.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society